A Randomized, Rater-Blinded, Crossover Study of the Effects of Oxymorphone Extended Release, Fed versus Fasting, on Cognitive Performance as Tested with CANTAB in Opioid-Tolerant Subjects. Issue 2 (13th February 2014)
- Record Type:
- Journal Article
- Title:
- A Randomized, Rater-Blinded, Crossover Study of the Effects of Oxymorphone Extended Release, Fed versus Fasting, on Cognitive Performance as Tested with CANTAB in Opioid-Tolerant Subjects. Issue 2 (13th February 2014)
- Main Title:
- A Randomized, Rater-Blinded, Crossover Study of the Effects of Oxymorphone Extended Release, Fed versus Fasting, on Cognitive Performance as Tested with CANTAB in Opioid-Tolerant Subjects
- Authors:
- Spierings, Egilius L. H.
Volkerts, Edmund R.
Heitland, Ivo
Thomson, Heather - Abstract:
- Abstract: Background: The maximum plasma concentration (Cmax ) of oxymorphone extended release (ER) 20 mg and 40 mg is approximately 50% higher in fed than in fasted subjects, with most of the difference in area-under-the-curve (AUC) occurring in the first 4 hours post-dose. Hence, the US FDA recommends in the approved labeling that oxymorphone ER is taken at least 1 hour before or 2 hours after eating. Methods: In order to determine the potential impact on cognitive performance of the increased absorption of oxymorphone ER, fed versus fasting, we conducted a randomized, rater-blinded, crossover study in 30 opioid-tolerant subjects, using tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB). The subjects randomly received 40 mg oxymorphone ER after a high-fat meal of approximately 1, 010 kCal or after fasting for 8–12 hours, and were tested 1 hour and 3 hours post-dose. Results: The CANTAB tests, Spatial Recognition Memory (SRM) and Spatial Working Memory (SWM), showed no statistically significant differences between the fed and fasting conditions. However, sustained attention, as measured by the Rapid Visual Information Processing (RVP) CANTAB test, showed a statistically significant interaction of fed versus fasting and post-dose time of testing ( F [1, 28] = 6.88, P = 0.01), suggesting that 40 mg oxymorphone ER after a high-fat meal versus fasting mitigates the learning effect in this particular cognition domain from 1 hour to 3 hours post-dose.Abstract: Background: The maximum plasma concentration (Cmax ) of oxymorphone extended release (ER) 20 mg and 40 mg is approximately 50% higher in fed than in fasted subjects, with most of the difference in area-under-the-curve (AUC) occurring in the first 4 hours post-dose. Hence, the US FDA recommends in the approved labeling that oxymorphone ER is taken at least 1 hour before or 2 hours after eating. Methods: In order to determine the potential impact on cognitive performance of the increased absorption of oxymorphone ER, fed versus fasting, we conducted a randomized, rater-blinded, crossover study in 30 opioid-tolerant subjects, using tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB). The subjects randomly received 40 mg oxymorphone ER after a high-fat meal of approximately 1, 010 kCal or after fasting for 8–12 hours, and were tested 1 hour and 3 hours post-dose. Results: The CANTAB tests, Spatial Recognition Memory (SRM) and Spatial Working Memory (SWM), showed no statistically significant differences between the fed and fasting conditions. However, sustained attention, as measured by the Rapid Visual Information Processing (RVP) CANTAB test, showed a statistically significant interaction of fed versus fasting and post-dose time of testing ( F [1, 28] = 6.88, P = 0.01), suggesting that 40 mg oxymorphone ER after a high-fat meal versus fasting mitigates the learning effect in this particular cognition domain from 1 hour to 3 hours post-dose. Conclusion: Oxymorphone 40 mg ER affected cognitive performance similarly within 3 hours post-dose, whether given on an empty stomach or after a high-fat meal, suggesting that the effect of food on plasma concentration may not be relevant in the medication's impact on cognition. … (more)
- Is Part Of:
- Pain medicine. Volume 15:Issue 2(2014)
- Journal:
- Pain medicine
- Issue:
- Volume 15:Issue 2(2014)
- Issue Display:
- Volume 15, Issue 2 (2014)
- Year:
- 2014
- Volume:
- 15
- Issue:
- 2
- Issue Sort Value:
- 2014-0015-0002-0000
- Page Start:
- 264
- Page End:
- 271
- Publication Date:
- 2014-02-13
- Subjects:
- Oxymorphone -- Fed -- Fasting -- High-Fat Meal -- CANTAB -- Cognitive Performance -- Chronic Nonmalignant Pain -- Opioid-Tolerant Subjects -- Crossover Study
Pain -- Periodicals
Pain -- Treatment -- Periodicals
Analgesics -- Periodicals
Pain -- Periodicals
Pain Management -- Periodicals
Douleur -- Périodiques
Douleur -- Traitement -- Périodiques
Analgésiques -- Périodiques
Analgésique
Soulagement de la douleur
Périodique électronique (Descripteur de forme)
Ressource Internet (Descripteur de forme)
616.047205 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1526-2375;screen=info;ECOIP ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1526-4637 ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=pme ↗
http://painmedicine.oxfordjournals.org/ ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/pme.12307 ↗
- Languages:
- English
- ISSNs:
- 1526-2375
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6333.806000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25191.xml